NCT01881204

Hesperidin and Bone Health in Postmenopausal Women

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Purdue University · Academic / Other
• Sex: Female
• Age: —
• Healthy volunteers: Accepted

Summary

The primary objective of this clinical trial is to test hesperidin with and without CALCILOCK® for bone resorption suppressing effect in postmenopausal women. The secondary objective is the comparison between 41Ca technology and classical biomarker to evaluate bone resorption.

Detailed description

Subjects will participate in four phases of the study: Baseline of 50 days and three intervention phases which include 50 days receiving product followed by 50 days of recovery. The total duration of the study will be 350 days. If participant has not been previously labeled with 41Ca, a 150 day period is added to the study. Hesperidin (552mg) and Calcilock® (amount per day: Calcium: 684 mg; Phosphorus: 282mg; Magnesium: 102mg; Zinc: 2.86mg; Vitamin C: 20 mg; Vitamin K1: 28µg; Vitamin D: 1.86µg) will be administered in the form of cookies (biscuit).

Conditions

• Osteoporosis, Postmenopausal

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Hesperidin and Calcilock	Hesperidin (552mg) and Calcilock® (amount per day: Calcium: 684 mg; Phosphorus: 282mg; Magnesium: 102mg; Zinc: 2.86mg; Vitamin C: 20 mg; Vitamin K1: 28µg; Vitamin D: 1.86µg) will be administered in the form of cookies (biscuit).
DIETARY_SUPPLEMENT	Hesperidin	Hesperidin (552mg) will be administered in the form of cookies (biscuit).
DIETARY_SUPPLEMENT	Control	Cookies without Hesperidin or Calcilock added.

Timeline

• Start date: 2011-04-01
• Primary completion: 2012-10-01
• Completion: 2012-10-01
• First posted: 2013-06-19
• Last updated: 2018-05-17

Locations

1 site across 1 country: United States